MorphoSys priced the shares at €44.50 apiece. The issue was several times over-subscribed, the company said.
The company said the proceeds will enable it to raise its cash balance to approximately €60 million. Additionally, the funding "allows us the flexibility to further expand the research antibody side of our business," CFO Dave Lemus said in a statement.
WestLB AG acted as lead manager of the transaction with DZ BANK as co-lead manager.